We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+39.74%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$210M
AUM Growth
+$79.2M
(+60%)
Cap. Flow
+$54.6M
Cap. Flow
% of AUM
25.98%
Top 10 Holdings %
Top 10 Hldgs %
63.23%
Holding
36
New
15
Increased
9
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$9.59M |
| 2 |
Arvinas
ARVN
|
+$5.57M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
+$5.5M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$5.47M |
| 5 |
DERM
Dermira, Inc.
DERM
|
+$5.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$6.31M |
| 2 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$2.24M |
| 3 |
Veracyte
VCYT
|
+$1.16M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$728K |
| 5 |
Outlook Therapeutics
OTLK
|
+$15K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.71% |
| 2 | Miscellaneous | 1.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
QTNT
26
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $2.52M | 1.2% |
+7,000
| New | +$2.46M |
|
|
AMRN
27
Amarin Corp
AMRN
$293M
| $1.82M | 0.86% |
4,375
-17,500
| -80% | -$6.31M |
|
28
Gossamer Bio
GOSS
$73M
| $1.3M | 0.62% |
+750
| New | +$1.25M |
|
|
ALLK
29
DELISTED
Allakos
ALLK
| $547K | 0.26% |
+13,500
| New | +$546K |
|
30
Sutro Biopharma
STRO
$257M
| $518K | 0.25% |
4,550
| – | – |
|
|
CEMI
31
DELISTED
Chembio diagnostics, Inc.
CEMI
| $231K | 0.11% |
41,667
-345,500
| -89% | -$2.24M |
|
32
BioCryst Pharmaceuticals
BCRX
$2.22B
| $204K | 0.1% |
25,000
| – | – |
|
33
PUT
Novavax
NVAX
$1.65B
| $138K | 0.07% |
+12,500
| New | +$395K |
|
|
34
Outlook Therapeutics
OTLK
$166M
| – | – |
-182
| Closed | -$15K |
|
35
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.7B
| – | – |
-100,000
| Closed | -$7.17M |
|
|
IMMU
36
PUT
DELISTED
Immunomedics Inc
IMMU
| – | – |
-400,000
| Closed | -$5.71M |
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q1 2019 Portfolio in Review
As of Q1 2019, Acuta Capital Partners held 36 positions worth $210M, up 60% from $131M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Acuta Capital Partners deployed $54.6M of net new capital in Q1 2019, opening 15 new positions and adding to 9 existing holdings. Its largest new stake was Insmed: 370,000 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 89% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Amarin Corp, an estimated $6.31M trimmed.
- Acuta Capital Partners's largest Q1 2019 buy was Insmed: 370,000 shares worth $10.8M.
- Acuta Capital Partners added most to ViewRay, Inc. in Q1 2019, an estimated $3.88M increase.
- Acuta Capital Partners's biggest Q1 2019 reduction was Amarin Corp, cutting an estimated $6.31M.
- Acuta Capital Partners fully exited Outlook Therapeutics in Q1 2019, selling an estimated $15K.
- Acuta Capital Partners's ten largest holdings make up 63% of its $210M portfolio in Q1 2019.
- Acuta Capital Partners opened 15 new positions and closed 3 in Q1 2019.
- Acuta Capital Partners's portfolio value rose 60% quarter-over-quarter to $210M.
Based on Acuta Capital Partners's 13F filing for Q1 2019, filed 14 May 2019.